	US 11,834,653 B2
	Methods and compositions for identifying epitopes
Stephen Elledge, Brookline, MA (US); Tomasz Kula, Brookline, MA (US); and Mohammad Haj Dezfulian, Boston, MA (US)
Assigned to The Brigham and Women's Hospital, Inc., Boston, MA (US)
Appl. No. 16/619,859
Filed by The Brigham and Women's Hospital, Inc., Boston, MA (US)
PCT Filed Jun. 8, 2018, PCT No. PCT/US2018/036663 § 371(c)(1), (2) Date Dec. 5, 2019, PCT Pub. No. WO2018/227091, PCT Pub. Date Dec. 13, 2018.
Claims priority of provisional application 62/516,977, filed on Jun. 8, 2017.
Prior Publication US 2020/0102553 A1, Apr. 2, 2020
Int. Cl. C12N 15/10 (2006.01); C12N 5/0783 (2010.01); C12N 5/09 (2010.01); C40B 20/04 (2006.01); C40B 40/02 (2006.01); G01N 33/50 (2006.01)

CPC C12N 15/1037 (2013.01) [C12N 5/0636 (2013.01); C12N 5/0693 (2013.01); C40B 20/04 (2013.01); C40B 40/02 (2013.01); G01N 33/5047 (2013.01); C12N 2529/10 (2013.01); G01N 2333/96436 (2013.01)]

22 Claims

1. An antigen presenting cell (APC) comprising:

a) an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with WIC class I or WIC class II molecules;

b) a molecular reporter of Granzyme B (GzB) activity; and

c) an exogenous nucleic acid encoding inhibitor of caspase-activated deoxyribonuclease (ICAD) in expressible form, an exogenous inhibitory nucleic acid targeting caspase-activated deoxyribonuclease (CAD), a CAD knockout, or a caspase knockout.